Colcemid treatment of myeloma prior to cell fusion increases the yield of hybridomas between myeloma and splenocyte.
Effect of Colcemid treatment of myeloma (X63-Ag8-6.5.3.) prior to fusion with mouse spleen cell was studied in terms of hybridoma formation. Spleen cells from BALB/c mice immunized with various soluble antigens were fused with the myeloma cells by using polyethylene glycol solution. Colcemid treatment of myeloma cells prior to fusion increased the average number of hybridoma colonies per well by 26-570%. The yield of hybridomas producing antigen-specific antibodies was also higher with the Colcemid treatment. The results suggest that most of the proliferative hybridomas are formed by fusion of cells in the M-phase of the cell cycle.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis; D003703:Demecolcine / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006825:Hybridomas / Q000032:analysis / Q000166:cytology*; D008722:Methods; D051379:Mice; D008807:Mice, Inbred BALB C; D009101:Multiple Myeloma / Q000473:pathology*; D013154:Spleen / Q000166:cytology*
D000911:Antibodies, Monoclonal; D003703:Demecolcine